As an Executive-in-Residence, Scott provides consulting services to early-stage pharmaceutical, biotechnology and medical device companies. He has more than 20 years of experience in various aspects of drug development and strategic clinical research and is an executive leader in the translation of therapies from concept to clinic with the delivery of clinical data in time for key financing and strategic decision making. He was previously the Executive Director of Emerging Therapies at Precigen Therapeutics and Head of Heart Failure Drug Development at Juventas Therapeutics. Currently, he is also CEO of CavoGene. Scott earned his B.S. at the University of Dayton, his M.S. at The Ohio State University and his Ph.D. at the University of Maryland.